Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers (DP-PAN-CANCER)

Institut Claudius Regaud

Status: Enrolling

Conditions: Upper Aerodigestive Tract Carcinoma; Adenocarcinoma of Endometrium; Prostate Adenocarcinoma; Nonseminomatous Germ Cell Tumor; Renal Cancer; Urothelial Carcinoma; Soft Tissue Sarcoma (STS); Seminomatous Germ Cell Tumor; Cervical Carcinoma; Cutaneous Melanoma

Treatments: Other: For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:

Study type: Interventional

Funder types: Other

Identifiers

NCT06967961

24GENE19

Details and patient eligibility

About

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis.

Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer.

450 patients will be enrolled in total.

Enrollment: 450 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors
• 2. Metastatic disease for which the treatment (whatever the line) has not been initiated yet
• 3. Age ≥ 18 years
• 4. Patient affiliated to a French Social Security scheme
• 5. Patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study.

Exclusion criteria

• 1. Patient with localized disease.
• 2. Pregnant or breast-feeding women.
• 3. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol.
• 4. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

450 participants in 1 patient group

Patients with metastatic cancer

Other group

Description:

* Blood sample collection for circulating DP cell detection by flow cytometry and Cell Search analysis for the following patients: * Cohort 1 : urothelial carcinoma * Cohort 2 : renal carcinoma * Cohort 3 : prostate adenocarcinoma * Cohort 4 : upper aerodigestive tract carcinoma * Cohort 5 : cervical carcinoma * Cohort 6 : adenocarcinoma of endometrium * Blood sample collection for circulating DP cell detection by flow cytometry and Parsotix analysis for the following patients: * Cohort 7 : cutaneous melanoma * Cohort 8 : soft tissue sarcoma * Cohort 9 : seminomatous and nonseminomatous germ cell tumors

Treatment:

Other: For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes: